ReviewGut microbes2019
Gut microbiota as a source of novel antimicrobials.
Review in Gut microbes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed.
- Gut microbiome and pregnancy complications: emerging evidence and mechanistic insights.Gut microbes · 2026Review
- From predicted bacteriocins to ecological function.Current research in microbial sciences · 2026Review
- Gut-on-Chip Models for Host-Microbiome Studies: A Systematic Review.Microorganisms · 2026Review
- Resistome and microbiome-immune interactions in an Eastern European population with high antibiotic use.Microbiology spectrum · 2026Article
- The human microbiome as a source of novel bioactive natural products: structures, bioactivities, and biosynthetic insights.Journal of natural medicines · 2026Review
- Molecular and Immunological Mechanisms Underlying the Anticancer Effects of Bifidobacterium.Probiotics and antimicrobial proteins · 2026Review
- Modulation of microbial community and metabolism throughJournal of animal science and technology · 2026Article
- Functional genetic signatures of the gut microbiome in cardiometabolic diseases: mechanisms and translational opportunities.Frontiers in microbiomes · 2026Review
- Review
- Complete Genome Sequence Analysis and Probiotic Characterisation ofMicroorganisms · 2025Article
- Bioactive Plasmid- and Phage-Encoded Antimicrobial Peptides (AMPs) in the Human Gut: A Metatranscriptome-Virome Profiling Reveals Exploratory Links to Metabolic Human Diseases.Microbial ecology · 2025Article
- Systematically investigating and identifying bacteriocins in the human gut microbiome.Cell genomics · 2025Article
- The Molecular Interplay Between Oral Microbiome and Oral Cancer Pathogenesis.International journal of molecular sciences · 2025Review
- The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential.Archives of microbiology · 2025Review
- The resident gut microbiome modulates the effect of synbiotics on the immunogenicity after SARS-COV-2 vaccination in elderly and diabetes patients.NPJ biofilms and microbiomes · 2025Article
- Emerging probiotics: future therapeutics for human gut health.FEMS microbiology ecology · 2025Article
- Emerging nanocarrier systems for the enhanced delivery of active pharmaceutical ingredients to the intestine.Nanomedicine (London, England) · 2025Review
- In Vitro Influence of Specific Bacteroidales Strains on Gut and Liver Health Related to Metabolic Dysfunction-Associated Fatty Liver Disease.Probiotics and antimicrobial proteins · 2025Article
- The apple of discord: can spider cocoons be equipped with antimicrobial factors?-a systematic review.Frontiers in zoology · 2025Review
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bacteria, Archaea, Eukarya and viruses coexist in the human gut, and this coexistence is functionally balanced by symbiotic or antagonistic relationships. Antagonism is often characterized by the production of antimicrobials against other organisms occupying the same environmental niche. Indeed, close co-evolution in the gut has led to the development of specialized antimicrobials, which is attracting increased attention as these may serve as novel alternatives to antibiotics and thereby help to address the global problem of antimicrobial resistance. The gastrointestinal (GI) tract is especially suitable for finding novel antimicrobials due to the vast array of microbes that inhabit it, and a considerable number of antimicrobial producers of both wide and narrow spectrum have been described. In this review, we summarize some of the antimicrobial compounds that are produced by bacteria isolated from the gut environment, with a special focus on bacteriocins. We also evaluate the potential therapeutic application of these compounds to maintain homeostasis in the gut and the biocontrol of pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.